All sectors of the present human lifecycle are immensely affected by sudden COVID-19 waves. This started the massive vaccination drive among a larger population in order to boost immunity & regain normalcy.
It is indirect protection, community immunity, or shielding achieved by immunizing an adequately large percentage of the population against an infection. Herd immunity decreases the epidemic’s threat, offers disease resistance, reduces the chances of infected individuals & susceptible individuals contact & hinders infection spread. For individuals who are difficult to be vaccinated like new-born & people with compromised immunity, herd immunity provides infection defence.
It can be acquired in 2 ways.
Infection- This occurs post-infection exposure leading to the development of protective antibodies & natural immunity during the recovery period.
Vaccination- This is done by vaccinating the majority of the population & building immunity without causing the real infection. Usefulness is determined by vaccine effectiveness in transmission reduction, target pathogen transmissibility & achievable vaccine coverage population.
Percentage of disease-immune people that are notably responsible for decreasing sequential infection spread.
It is calculated as 1-1/R0, where R0 is a critical variable. In an immunologically susceptible population, R0 is the average number of secondary cases caused by infected individuals Social and demographic elements such as population density, public health measures, & cultural attitudes and behaviours impact R0, inevitably resulting in noticeable disparity in HIT predictions.
Disease transfer continues if in case the proportion of vaccinated people evaluated is below the calculated HIT.
• Vaccine hesitancy due to religious objections, fears & mistrust about the vaccine benefits
• Questionable vaccine protection & unclarity about immunity towards new variants • Uneven vaccine launch, distribution & frequent infection outbreaks
• Distress of vaccine-related complications like soreness, swelling, fever & rashes
A sufficient HIT cannot be achieved in countries with low seroprevalence even after finishing all adult vaccination, if there is a high number of children population, although infection impact can be reduced among high-risk populations.
SARS-CoV-2 control should not only be predicted by considering herd immunity as an accurate biological parameter.
Along with herd immunity-focused pandemic controlling tools should be utilized to diminish viral movement-related illness.
Strengthening herd immunity will surely decrease infection likelihood, reinfection & hospitalization.
Vaccination, completing required doses along with booster doses & restricting virus mutation decides the timespan to secure herd immunity.
Vaccine update & alternative treatment development relies on the steady sustained global examination & investigation of COVID-19 variants. This will prevent emerging new variants associated with herd immunity decline & infection risk to the unvaccinated populations which may lead to alarming illnesses.
Accomplishing herd immunity is difficult & demanding. It requires worldwide immunization campaigning, mass vaccine-related awareness & distinct vaccine administration.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation